CytoSorbents Corporation (CTSO)

[cars100cars]

Another great quarter in the books. Sales doubled last year and will continue on trend in 2017. Remember, a full year of reimbursement by third parties is ahead in Germany. More third-party EU approvals are likely ahead. Indications for use are increasing. The African distributorship also indicates increased interest in using CytoSorb for serious infections. Fresenius is pumping Cytosorb. There are too many catalysts in place to drive revenues and earnings higher this year. It takes a long time to build a company like this with a unique medical disposable product. Momentum is growing. Margins are excellent, reorder patterns are excellent and expansion into new markets is excellent. Plus, the FDA Cardiac Surgery Pilot study results are excellent, with CTSO gaining early awareness among cardiac docs. These are good indications the FDA will likely give approval for a pivotal Cardiac Surgery trial to start this year. 2018 approval is a possibility and cardiac docs want this product which can control free hemoglobin. Ignore all the positives are your peril. At today's price, this is the best growth stock bargain available anywhere. Slappie, you might be bearish and even short CTSO. You sure don't know this company from your remarks. Stay in that short position and you will be badly hurt. This stock can return to $5.50 in an eyeblink, and then run higher from there.